Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Ovarian Cancer News

News
Interventions Improve Symptom Controllability Among Patients With Recurrent Ovarian Cancers
02/24/2022
Study findings revealed the web-based WRITE Symptoms interventions significantly improved symptom controllability for patients with ovarian cancer, regardless of delivery method.
Study findings revealed the web-based WRITE Symptoms interventions significantly improved symptom controllability for patients with ovarian cancer, regardless of delivery method.
Study findings revealed the...
02/24/2022
Journal of Clinical Pathways

Advertisement

News
Cost-Effectiveness of Opportunistic Salpingectomy at the Time of Laparoscopic Cholecystectomy for Ovarian Cancer Prevention
02/24/2022
Opportunistic salpingectomy at the time of elective cholecystectomy may be a cost-effective strategy to prevent ovarian cancer among average risk women.
Opportunistic salpingectomy at the time of elective cholecystectomy may be a cost-effective strategy to prevent ovarian cancer among average risk women.
Opportunistic salpingectomy at...
02/24/2022
Journal of Clinical Pathways
News
Preferences for Second-Line PARP Inhibitor Maintenance in Ovarian Cancer
12/09/2021
Findings from a recent study analyzing patients' and oncologists' preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer indicate that PFS gains observed in selected studies of PARP inhibitors may be worth...
Findings from a recent study analyzing patients' and oncologists' preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer indicate that PFS gains observed in selected studies of PARP inhibitors may be worth...
Findings from a recent study...
12/09/2021
Journal of Clinical Pathways
News
Real-World Utilization of PARP Inhibitors for Ovarian Cancer in the United States
11/19/2021
Study findings highlight the differences in tolerability profiles, treatment adherence, and health economics between three available PARP inhibitors for ovarian cancer.
Study findings highlight the differences in tolerability profiles, treatment adherence, and health economics between three available PARP inhibitors for ovarian cancer.
Study findings highlight the...
11/19/2021
Journal of Clinical Pathways

Advertisement

News
Physician Variation in End-of-Life Care Among Women With Ovarian Cancer
11/02/2021
A study examining physician variation in aggressive end-of-life care among women dying of ovarian cancer suggests that interventions aimed at physician practices and decision making in end-of-life care are needed to improve the quality of...
A study examining physician variation in aggressive end-of-life care among women dying of ovarian cancer suggests that interventions aimed at physician practices and decision making in end-of-life care are needed to improve the quality of...
A study examining physician...
11/02/2021
Journal of Clinical Pathways
News
Neoadjuvant Chemotherapy Appropriate for First-Line Treatment of Advanced Ovarian Cancer
10/21/2021
Cancer programs with high use of neoadjuvant chemotherapy achieved greater improvement in short-term mortality and equivalent gains in median overall survival compared to those with low use of neoadjuvant chemotherapy.
Cancer programs with high use of neoadjuvant chemotherapy achieved greater improvement in short-term mortality and equivalent gains in median overall survival compared to those with low use of neoadjuvant chemotherapy.
Cancer programs with high use of...
10/21/2021
Journal of Clinical Pathways
News
Real-World Olaparib Maintenance Therapy for BRCA-Mutated, Recurrent Ovarian Cancer
09/09/2021
Findings from a recent real-world study suggest that olaparib maintenance is both safe and effective for the treatment of BRCA-mutated recurrent ovarian cancer.
Findings from a recent real-world study suggest that olaparib maintenance is both safe and effective for the treatment of BRCA-mutated recurrent ovarian cancer.
Findings from a recent...
09/09/2021
Journal of Clinical Pathways

Advertisement

News
Maintenance Therapy Use for Recurrent Ovarian Cancer Increasing in Real-World Setting
09/02/2021
Study findings suggest maintenance therapy is becoming more common following second-line or third-line platinum-based chemotherapy in patients with platinum-sensitive recurrent ovarian cancer.
Study findings suggest maintenance therapy is becoming more common following second-line or third-line platinum-based chemotherapy in patients with platinum-sensitive recurrent ovarian cancer.
Study findings suggest...
09/02/2021
Journal of Clinical Pathways
News
Cost-Effectiveness of Olaparib vs Niraparib as a Maintenance Regimen for Ovarian Cancer
08/18/2021
Findings from recent study indicate olaparib is more cost-effective than niraparib for maintenance therapy in patients with recurrent platinum-sensitive ovarian cancer.
Findings from recent study indicate olaparib is more cost-effective than niraparib for maintenance therapy in patients with recurrent platinum-sensitive ovarian cancer.
Findings from recent study...
08/18/2021
Journal of Clinical Pathways
News
Maintenance Therapy Patterns for Recurrent Ovarian Cancer in Real-World Setting
08/04/2021
Findings from a real-world suggest maintenance therapy is becoming more common following second- or third-line platinum-based chemotherapy for ovarian cancer, regardless of biomarker status.
Findings from a real-world suggest maintenance therapy is becoming more common following second- or third-line platinum-based chemotherapy for ovarian cancer, regardless of biomarker status.
Findings from a real-world...
08/04/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP September/October 2024 Issue

Current Issue

October 2024
Volume 10
Issue 5
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use